Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft HG, Arseniev L, Beier R, Beutel G, Cario G, Fröhlich B, Greil J, Hansmann L, Hasenkamp J, Höfs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kröger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt HC, Sala E, Sauer MG, Schmitt C, Schroers R, Steckel NK, Trappe RU, Verbeek M, Wolff D, Blasczyk R, Eiz-Vesper B, Maecker-Kolhoff B. Bonifacius A, et al. Among authors: verbeek m. J Clin Invest. 2023 Jun 15;133(12):e163548. doi: 10.1172/JCI163548. J Clin Invest. 2023. PMID: 37159273 Free PMC article.
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report.
Wicklein R, Heidegger S, Verbeek M, Eiz-Vesper B, Maecker-Kolhoff B, Kirschke JS, Page A, Korn T, Hemmer B, Deschauer M. Wicklein R, et al. Among authors: verbeek m. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 20;8(5):e1042. doi: 10.1212/NXI.0000000000001042. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34285093 Free PMC article.
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M. Nagler A, et al. Among authors: verbeek m. Bone Marrow Transplant. 2022 Jul;57(7):1116-1123. doi: 10.1038/s41409-022-01693-8. Epub 2022 Apr 30. Bone Marrow Transplant. 2022. PMID: 35501565
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M. Nagler A, et al. Among authors: verbeek m. Bone Marrow Transplant. 2022 Dec;57(12):1854. doi: 10.1038/s41409-022-01834-z. Bone Marrow Transplant. 2022. PMID: 36207624 No abstract available.
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Bug G, Labopin M, Niittyvuopio R, Stelljes M, Reinhardt HC, Hilgendorf I, Kröger N, Kaare A, Bethge W, Schäfer-Eckart K, Verbeek M, Mielke S, Carlson K, Bazarbachi A, Spyridonidis A, Savani BN, Nagler A, Mohty M. Bug G, et al. Among authors: verbeek m. Bone Marrow Transplant. 2023 Jun;58(6):710-716. doi: 10.1038/s41409-023-01965-x. Epub 2023 Mar 31. Bone Marrow Transplant. 2023. PMID: 37002412 Free PMC article.
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner EM, Biersack H, Schäfer-Eckart K, Wolf D, Stuhler G, Reibke R, Schmid C, Kaufmann M, Eder M, Bertz H, Grishina O. Finke J, et al. Among authors: verbeek m. Bone Marrow Transplant. 2024 Mar 16. doi: 10.1038/s41409-024-02264-9. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38493275
Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner EM, Biersack H, Schäfer-Eckart K, Wolf D, Stuhler G, Reibke R, Schmid C, Kaufmann M, Eder M, Bertz H, Grishina O. Finke J, et al. Among authors: verbeek m. Bone Marrow Transplant. 2024 Apr 23. doi: 10.1038/s41409-024-02274-7. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38654115 No abstract available.
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU. Neuenhahn M, et al. Among authors: verbeek m. Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16. Leukemia. 2017. PMID: 28090089 Clinical Trial.
Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation.
Wagner-Drouet E, Teschner D, Wolschke C, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Hilgendorf I, Klein S, Verbeek M, Ditschkowski M, Koch M, Lindemann M, Schmidt T, Rascle A, Barabas S, Deml L, Wagner R, Wolff D. Wagner-Drouet E, et al. Among authors: verbeek m. Diagnostics (Basel). 2021 Feb 15;11(2):312. doi: 10.3390/diagnostics11020312. Diagnostics (Basel). 2021. PMID: 33671952 Free PMC article.
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Koch K, Henning L, Kobbe G, Haas R, Alakel N, Röhnert MA, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T, Middeke JM. Rautenberg C, et al. Among authors: verbeek m. Blood Cancer J. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5. Blood Cancer J. 2021. PMID: 34608129 Free PMC article. Clinical Trial.
462 results